

Yuan-Kai Shi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3996164/publications.pdf>

Version: 2024-02-01

135
papers

6,745
citations

159525

30
h-index

71651

76
g-index

155
all docs

155
docs citations

155
times ranked

8392
citing authors

#	ARTICLE	IF	CITATIONS
1	A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER). <i>Journal of Thoracic Oncology</i> , 2014, 9, 154-162.	0.5	1,131
2	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 577-589.	5.1	950
3	Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. <i>Lancet Oncology</i> , The, 2013, 14, 953-961.	5.1	389
4	Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 1569.	3.4	388
5	The global implications of diabetes and cancer. <i>Lancet</i> , The, 2014, 383, 1947-1948.	6.3	327
6	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 867-875.	0.5	260
7	Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). <i>Journal of Hematology and Oncology</i> , 2020, 13, 143.	6.9	226
8	Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). <i>British Journal of Cancer</i> , 2018, 118, 654-661.	2.9	192
9	Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , the, 2019, 6, e12-e19.	2.2	176
10	Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, 681-690.	5.2	166
11	Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. <i>Journal of Hematology and Oncology</i> , 2017, 10, 69.	6.9	155
12	Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances. <i>Leukemia</i> , 2021, 35, 312-332.	3.3	151
13	Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1539-1548.	0.5	146
14	Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study. <i>PLoS ONE</i> , 2015, 10, e0143515.	1.1	143
15	Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. <i>ESMO Open</i> , 2017, 2, e000219.	2.0	87
16	Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 678-689.	5.1	83
17	Plasma Levels of Heat Shock Protein 90 Alpha Associated with Lung Cancer Development and Treatment Responses. <i>Clinical Cancer Research</i> , 2014, 20, 6016-6022.	3.2	80
18	Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. <i>American Journal of Hematology</i> , 2018, 93, 607-614.	2.0	75

#	ARTICLE	IF	CITATIONS
19	Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 152-161.	0.7	66
20	Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, 877-887.	1.6	58
21	Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors. <i>JAMA Network Open</i> , 2020, 3, e2013201.	2.8	54
22	VTE Risk Profiles and Prophylaxis in Medical and Surgical Inpatients. <i>Chest</i> , 2019, 155, 114-122.	0.4	51
23	Chinese guidelines on the diagnosis and treatment of primary lung cancer (2015 version). <i>Cancer</i> , 2015, 121, 3165-3181.	2.0	47
24	miR-130a regulates macrophage polarization and is associated with non-small cell lung cancer. <i>Oncology Reports</i> , 2015, 34, 3088-3096.	1.2	47
25	Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study. <i>European Journal of Cancer</i> , 2020, 130, 182-192.	1.3	46
26	Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. <i>Thoracic Cancer</i> , 2019, 10, 551-556.	0.8	42
27	Ramosetron versus Ondansetron in the Prevention of Chemotherapy-Induced Gastrointestinal Side Effects: A Prospective Randomized Controlled Study. <i>Chemotherapy</i> , 2007, 53, 44-50.	0.8	39
28	A MicroRNA Signature Predicts Survival in Early Stage Small-Cell Lung Cancer Treated with Surgery and Adjuvant Chemotherapy. <i>PLoS ONE</i> , 2014, 9, e91388.	1.1	39
29	Current management of chemotherapy-induced neutropenia in adults: key points and new challenges. <i>Cancer Biology and Medicine</i> , 2020, 17, 896-909.	1.4	35
30	Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 122, 32-37.	0.9	32
31	Antitumor Effects of a Novel Chromosome Region Maintenance 1 (CRM1) Inhibitor on Non-Small Cell Lung Cancer Cells In Vitro and in Mouse Tumor Xenografts. <i>PLoS ONE</i> , 2014, 9, e89848.	1.1	32
32	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1569-1579.	1.2	31
33	Prognostic impact of mutation profiling in patients with stage II and III colon cancer. <i>Scientific Reports</i> , 2016, 6, 24310.	1.6	30
34	Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. <i>Oncologist</i> , 2019, 24, e1251-e1261.	1.9	29
35	The Molecular Detection and Clinical Significance of ALK Rearrangement in Selected Advanced Non-Small Cell Lung Cancer: ALK Expression Provides Insights into ALK Targeted Therapy. <i>PLoS ONE</i> , 2014, 9, e84501.	1.1	27
36	Current status and progress of lymphoma management in China. <i>International Journal of Hematology</i> , 2018, 107, 405-412.	0.7	26

#	ARTICLE	IF	CITATIONS
37	Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure. <i>Cancer Science</i> , 2018, 109, 3943-3952.	1.7	26
38	Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients. <i>Theranostics</i> , 2020, 10, 6399-6410.	4.6	26
39	Survival and pretreatment prognostic factors for extensive-stage small cell lung cancer: A comprehensive analysis of 358 patients. <i>Thoracic Cancer</i> , 2021, 12, 1943-1951.	0.8	26
40	Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors. <i>Journal of Hematology and Oncology</i> , 2019, 12, 9.	6.9	22
41	Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, e204429.	3.4	22
42	Anti-p53 autoantibody in blood as a diagnostic biomarker for colorectal cancer: A meta-analysis. <i>Scandinavian Journal of Immunology</i> , 2020, 91, e12829.	1.3	21
43	Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2413-2424.	2.0	21
44	Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study. <i>Haematologica</i> , 2022, 107, 1633-1642.	1.7	21
45	Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens. <i>Anti-Cancer Drugs</i> , 2013, 24, 641-647.	0.7	20
46	Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type. <i>Annals of Hematology</i> , 2017, 96, 1477-1483.	0.8	20
47	Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1857-1870.	0.5	19
48	Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma. <i>OncoTargets and Therapy</i> , 2016, 9, 2911.	1.0	18
49	Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma not otherwise specified. <i>Annals of Hematology</i> , 2017, 96, 245-251.	0.8	18
50	Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 7.	6.9	17
51	Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small cell lung cancer: A multicenter, randomized, double-blind, phase III trial. <i>Cancer Communications</i> , 2021, 41, 889-903.	3.7	16
52	PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL). <i>Journal of Clinical Oncology</i> , 2016, 34, 7506-7506.	0.8	16
53	Reply to "A promoter polymorphism in the CASP8 gene is not associated with cancer risk". <i>Nature Genetics</i> , 2008, 40, 260-261.	9.4	14
54	Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study. <i>Targeted Oncology</i> , 2019, 14, 149-158.	1.7	14

#	ARTICLE	IF	CITATIONS
55	Whole-genome sequencing of prostate cancer reveals novel mutation-driven processes and molecular subgroups. <i>Life Sciences</i> , 2020, 254, 117218.	2.0	14
56	The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study. <i>PLoS ONE</i> , 2015, 10, e0142500.	1.1	14
57	The prognostic utility and the association of serum light chains (free and total) and absolute lymphocyte count in patients with newly diagnosed diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2014, 38, 1291-1298.	0.4	13
58	Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas. <i>Hematology</i> , 2016, 21, 536-541.	0.7	13
59	First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 6.	6.9	13
60	Co-mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 6812-6821.	1.6	12
61	Molecular profiling of Chinese <sc>R–CHOP</sc> treated <sc>DLBCL</sc> patients: Identifying a high-risk subgroup. <i>International Journal of Cancer</i> , 2020, 147, 2611-2620.	2.3	12
62	Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase I dose-escalation and dose-expansion trial. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 25.	7.1	12
63	Sorafenib in metastatic radioactive iodine-refractory differentiated thyroid cancer: A pilot study. <i>Molecular and Clinical Oncology</i> , 2014, 2, 87-92.	0.4	11
64	A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2741-2746.	1.0	11
65	Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study. <i>Blood</i> , 2019, 134, 1568-1568.	0.6	11
66	Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal Metastases. <i>Current Cancer Drug Targets</i> , 2019, 19, 666-673.	0.8	11
67	Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. <i>Lung Cancer</i> , 2020, 150, 240-246.	0.9	10
68	Third-line treatment: A randomized, double-blind, placebo-controlled phase III ALTER-0303 study—Efficacy and safety of anlotinib treatment in patients with refractory advanced NSCLC.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9053-9053.	0.8	10
69	Comprehensive gene copy number alterations profiling predict efficacy of adjuvant chemotherapy in resected stage II-IIIa lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24278-e24278.	0.8	9
70	China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version). <i>Annals of Translational Medicine</i> , 2015, 3, 260.	0.7	9
71	Medication therapy of high-dose methotrexate: An evidence-based practice guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2456-2472.	1.1	9
72	Prognostic significance of baseline neutrophil-lymphocyte ratio in patients with non-small-cell lung cancer: a pooled analysis of open phase III clinical trial data. <i>Future Oncology</i> , 2022, 18, 1679-1689.	1.1	9

#	ARTICLE	IF	CITATIONS
73	A prognostic model for platinum doublet as second-line chemotherapy in advanced non-small cell lung cancer patients. <i>Cancer Medicine</i> , 2016, 5, 1116-1124.	1.3	8
74	Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy. <i>Journal of Translational Medicine</i> , 2019, 17, 339.	1.8	8
75	Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients. <i>Cancer Management and Research</i> , 2020, Volume 12, 11515-11522.	0.9	8
76	Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era. <i>Oncotarget</i> , 2016, 7, 72219-72228.	0.8	8
77	Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2015, 27, 239-46.	0.7	8
78	Gefitinib versus erlotinib as salvage treatment for lung adenocarcinoma patients who benefited from the initial gefitinib: A retrospective study. <i>Thoracic Cancer</i> , 2013, 4, 109-116.	0.8	7
79	Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma. <i>Chinese Journal of Cancer</i> , 2015, 34, 522-30.	4.9	7
80	Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 569-575.	0.6	7
81	Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial. <i>Cancer Communications</i> , 2018, 38, 1-9.	3.7	7
82	Clinicopathologic characteristics and outcome of patients with different EGFR mutations. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 166-171.	0.7	7
83	Phase 3 study of first-line crizotinib vs pemetrexed cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9058-9058.	0.8	7
84	Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1681-1691.	2.0	7
85	Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Cancer Biology and Medicine</i> , 2022, 19, 1-17.	1.4	7
86	CMAB009 plus irinotecan versus irinotecan only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial. <i>Cancer Communications</i> , 2019, 39, 1-13.	3.7	6
87	The pretreatment platelet count predicts survival outcomes of diffuse large B-cell lymphoma: An analysis of 1007 patients in the rituximab era. <i>Leukemia Research</i> , 2021, 110, 106715.	0.4	6
88	Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7596-7596.	0.8	6
89	Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6061-6061.	0.8	6
90	China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version). <i>Journal of Thoracic Disease</i> , 2015, 7, E468-72.	0.6	6

#	ARTICLE	IF	CITATIONS
91	Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases. <i>Oncology Research</i> , 2020, 28, 127-133.	0.6	5
92	Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (<scp>SCC</scp>): A post hoc analysis of the <scp>ALTER0303</scp> trial. <i>Thoracic Cancer</i> , 2021, 12, 2345-2351.	0.8	5
93	Effect of JS001, a monoclonal antibody targeting programmed death-1 (PD-1), on responses and disease control in patients with advanced or refractory alveolar soft part sarcoma: Results from a phase 1 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11572-11572.	0.8	5
94	Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 3071-3085.	2.0	5
95	Phase <scp>II</scp> trial of paclitaxel–carboplatin with intercalated gefitinib for untreated, epidermal growth factor receptor gene mutation status unknown non–small cell lung cancer. <i>Thoracic Cancer</i> , 2014, 5, 149-154.	0.8	4
96	Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas. <i>Chinese Medical Journal</i> , 2015, 128, 2498-2504.	0.9	4
97	Icotinib as initial treatment in lung adenocarcinoma patients with brain metastases. <i>Thoracic Cancer</i> , 2016, 7, 437-441.	0.8	4
98	Plasma Lipidomic Analysis to Identify Novel Biomarkers for Hepatocellular Carcinoma. <i>Journal of Analysis and Testing</i> , 2017, 1, 223-232.	2.5	4
99	Final overall survival and updated biomarker analysis results from the randomized phase III ICOGEN trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7559-7559.	0.8	4
100	Enhancement of the International prognostic index with β 2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
101	Analysis of clinicopathological features of the echinoderm microtubule-associated protein-like-4-anaplastic lymphoma kinase fusion gene in Chinese patients with advanced non-small-cell lung cancer. <i>Thoracic Cancer</i> , 2014, 5, 255-260.	0.8	3
102	Decreased Prognostic Value of International Prognostic Score in Chinese Advanced Hodgkin Lymphoma Patients Treated in the Contemporary Era. <i>Chinese Medical Journal</i> , 2016, 129, 2780-2785.	0.9	3
103	Validation of the IMPROVE bleeding risk score in Chinese medical patients during hospitalization: Findings from the dissolve-2 study. <i>The Lancet Regional Health - Western Pacific</i> , 2020, 4, 100054.	1.3	3
104	Sintilimab (IBI308) in relapsed/refractory classical Hodgkin lymphoma: A multicenter, single-arm phase 2 trial in China (ORIENT-1 study).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7536-7536.	0.8	3
105	Subgroup analysis of elderly patients (pts) in ALTER0303: Anlotinib hydrochloride as 3rd-line and further line treatment in refractory advanced NSCLC pts from a randomized, double-blind, placebo-controlled phase III ALTER0303 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21181-e21181.	0.8	3
106	Prevalence and management of pain in lung cancer patients in northern China: A multicenter cross–sectional study. <i>Thoracic Cancer</i> , 2022, 13, 1684-1690.	0.8	3
107	Chinese perspective of the role of primary care in cancer control. <i>Lancet Oncology</i> , The, 2015, 16, 1227-1228.	5.1	2
108	P2.03a-001 A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2017, 12, S886-S887.	0.5	2

#	ARTICLE	IF	CITATIONS
109	Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapy. <i>Journal of Translational Medicine</i> , 2021, 19, 399.	1.8	2
110	Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study. <i>Chinese Medical Journal</i> , 2022, 135, 433-440.	0.9	2
111	An open-label, randomized, multicenter, phase III study of S-1 and cisplatin versus docetaxel and cisplatin in patients with untreated advanced non-small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8039-8039.	0.8	2
112	Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2015, 27, 516-23.	0.7	2
113	Study of conditioning regimens with or without high-dose radiotherapy before autologous stem cell transplantation for treating aggressive lymphoma. <i>International Journal of Hematology</i> , 2009, 89, 106-112.	0.7	1
114	Ventana immunohistochemistry ALK (D5F3) detection of ALK expression in pleural effusion samples of lung adenocarcinoma. <i>Personalized Medicine</i> , 2015, 12, 349-357.	0.8	1
115	Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials: a cross-sectional study in China. <i>BMJ Open</i> , 2019, 9, e028589.	0.8	1
116	Identification of osimertinib resistance mechanisms in Chinese NSCLC patients: Analysis from AURA17 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9077-9077.	0.8	1
117	In vitro study on cryopreservation of peripheral blood stem cells with uncontrolled freezer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2002, 14, 235-239.	0.7	0
118	High dose chemoradiotherapy with autologous hematopoietic stem cell transplantation in the treatment of advanced Hodgkin's lymphoma: A report of 11 cases. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2002, 14, 254-258.	0.7	0
119	In Response. <i>Journal of Thoracic Oncology</i> , 2014, 9, e58-e59.	0.5	0
120	Development and validation of a UHPLC-MS/MS method for simultaneous quantitation the plasma concentration of Sabarubicin and its alcohol metabolite M3 in Chinese small cell lung cancer patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1025, 119-125.	1.2	0
121	Efficacy of icotinib in lung squamous cell cancer: A real world experience from single institution. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 379-384.	0.7	0
122	Recombinant human thrombopoietin prior to mobilization chemotherapy facilitates platelet recovery in autologous transplantation in patients with lymphoma: Results of a prospective randomized study. <i>Chronic Diseases and Translational Medicine</i> , 2021, 7, 190-198.	0.9	0
123	Phase I/II trial of sorafenib combined with FOLFOX4 in untreated patients with advanced gastric adenocarcinoma: Phase I results.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14606-e14606.	0.8	0
124	Autologous peripheral blood stem cell mobilization following high-dose CHOP chemotherapy combined with rituximab in patients with NHL.. <i>Journal of Clinical Oncology</i> , 2014, 32, e18003-e18003.	0.8	0
125	Comprehensive analysis of driver mutations in Chinese squamous cell lung carcinomas by targeted next-generation sequencing.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7544-7544.	0.8	0
126	Comprehensive genomic profiling of 443 patients with advanced renal cell carcinoma (RCC) to reveal clinically relevant genomic alterations and to aid in classification of rare subtypes.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19048-e19048.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Apatinib plus icotinib in treating advanced non-small-cell lung cancer after icotinib treatment failure.. Journal of Clinical Oncology, 2017, 35, e20528-e20528.	0.8	0
128	Whole exome sequencing identifies novel prognostic biomarker in colon cancer.. Journal of Clinical Oncology, 2017, 35, e15098-e15098.	0.8	0
129	An updated analysis of ICOGEN to demonstrate utility of a blood-based proteomic test to predict outcomes in EGFR TKI treated patients.. Journal of Clinical Oncology, 2017, 35, e20655-e20655.	0.8	0
130	Dynamic process of circulating tumour DNA (ctDNA) profiling as a predictor of efficacy of pemetrexed combined platinum chemotherapy in advanced lung adenocarcinoma.. Journal of Clinical Oncology, 2017, 35, e23048-e23048.	0.8	0
131	Rh-endostatin combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in NSCLC: A retrospective comparison with standard chemotherapy.. Journal of Clinical Oncology, 2018, 36, e21198-e21198.	0.8	0
132	Plinabulin (Plin), a small molecule with anti-cancer activity and a novel mechanism of action (MoA) in docetaxel (Tax)-induced neutropenia: Phase (I) 2 results from a head-to-head comparison with Pegfilgrastim (Peg).. Journal of Clinical Oncology, 2018, 36, 2528-2528.	0.8	0
133	BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study.. Journal of Clinical Oncology, 2018, 36, e21108-e21108.	0.8	0
134	The genome patterns of prostate cancer in national cancer center in China.. Journal of Clinical Oncology, 2018, 36, e17090-e17090.	0.8	0
135	A phase II trial with the combination of plinabulin (plin) pegfilgrastim (peg): Evaluation of the reversal of peg's immune-suppressive potential by the addition of plin to peg.. Journal of Clinical Oncology, 2019, 37, 4-4.	0.8	0